James Chopas - Jan 21, 2022 Form 4/A - Amendment Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
VP/Chief Accounting Officer
Signature
/s/ David Watson, attorney-in-fact
Stock symbol
APLS
Transactions as of
Jan 21, 2022
Transactions value $
$0
Form type
4/A - Amendment
Date filed
2/7/2022, 07:06 PM
Date Of Original Report
Jan 25, 2022
Previous filing
Oct 27, 2021
Next filing
Aug 31, 2022
SEC
View on sec.gov

Transactions Table

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (right to buy) Award $0 +15.1K $0.00 15.1K Jan 21, 2022 Common Stock 15.1K $35.46 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents a restricted stock unit grant made on January 21, 2022 that vests 25% annually in equal installments over four years from the date of grant, subject to continued service.
F2 On January 23, 2021, the reporting person filed a Form 4 that inadvertently reported that the reporting person was granted a restricted stock unit of 6,974 shares. This amendment is being filed solely to correct such number of shares to 10,657.
F3 This represents a non-qualified stock option grant made on January 21, 2022 that vests over a four year period with 25% vesting one year from grant date and the remaining 75% vesting in equal monthly installments thereafter through the fourth anniversary of the grant date, subject to continued service.
F4 On January 23, 2021, the reporting person filed a Form 4 that inadvertently reported that the reporting person was granted a non-qualified stock option grant of 9,892 shares. This is amendment is being filed solely to correct such number of shares to 15,116.